- Case report
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Severe generalised hypersensitivity reaction to topical neomycin after cataract surgery: a case report
© Ansari and Onyema; licensee BioMed Central Ltd. 2008
Received: 09 July 2007
Accepted: 23 February 2008
Published: 23 February 2008
Systemic hypersensitivity reactions to topical ophthalmic treatment occur rarely, but when they do they can be severe as highlighted by this case.
A post-operative cataract surgery patient developed a severe and generalised hypersensitivity reaction following topical treatment with Maxitrol (Dexamethasone and Neomycin) eye drops. The patient reported a previous allergic reaction to Neomycin.
This case report emphasises the importance of a thorough drug and allergy history when patients are seen at pre-assessment or clerked in for surgery.
Adverse external ocular effects of topical ophthalmic therapy have been estimated to occur in 10 % of all adverse reactions .
Drug-related ocular allergies are often the result of type IV hypersensitivity reactions, although type 1 and type 3 hypersensitivity reactions may also be involved .
Hypersensitivity to localised ocular therapy may involve a localised contact reaction which may include itching, redness, tearing, mucopurulent discharge, and papillary conjunctivitis as well as corneal involvement . Dermatitis, oedema and chemosis of the eyelids and skin can also occur .
Anaphylactoid reactions are rare and can be the result of type 1 (immediate) hypersensitivity reactions . They are not usually associated with systemic anaphylaxis but involve an acute shock syndrome that may be immunologically mediated .
Anaphylactoid reactions are characterised by acute itching, conjunctival hyperemia, chemosis and oedema of skin in the form of urticaria and angioedema Neomycin is an antibiotic that is often used in the form of Maxitrol (Neomycin, Polymyxin B and Dexamethasone) after cataract surgery in the prophylaxis of infection.
When used in ophthalmic preparations, it is well known to be a cause of allergic localised contact reactions, but it is rare for it to cause a diffuse cutaneous systemic reaction . One study has estimated the incidence of allergic contact reactions to topical neomycin as 1 to 29/100,000 . We describe a case of severe systemic allergy with a diffuse cutaneous hypersensitivity reaction following topical ophthalmic administration of neomycin in the form of Maxitrol.
An 80 year old Caucasian male underwent routine phacoemulsification cataract extraction with posterior chamber intraocular lens implant.
The patient had a history of hypertension and hypercholesterolemia for which he was using Atenolol and Simvastatin. He also had a history of bladder cancer for which he had received chemotherapy and radiotherapy.
Of note, the patient had reported an allergic reaction to Neomycin ear drops 30 years previously. This had left him with a rash that improved a few days later.
The patient was discharged after a straight forward cataract operation on Maxitrol eye drops four times a day.
He was seen the next day for the first post-operative visit, and up until then had used Maxitrol twice to the affected eye.
At that stage the patient's eye was noted to be slightly more injected than usual but no further concerns were raised. Papillae were noted on the palpebral conjunctiva and treatment was continued.
Treatment with systemic Prednisone 20 mg once a day and Betnovate eye ointment relieved his symptoms remarkably, and 3 weeks later all signs of inflammation were gone.
Systemic hypersensitivity reactions to topical ophthalmic treatment occur rarely. but when they do they can be severe as highlighted by this case.
Although the patient in this report had a substantial improvement in best-corrected visual acuity from counting fingers pre-operatively to 6/9 post-operatively, he endured a long and painful recovery which otherwise would have been quick and straight forward. An alternative post-operative regime could have been Pred Forte and Chloramphenicol eye drops four times a day.
This case report emphasises the importance of a thorough drug and allergy history when patients are seen at pre-assessment or clerked in for surgery. Even when drugs are given topically and locally, the possibility of a severe systemic reaction should always be borne in mind even though these are rare. As physicians it is also important for us to educate our patients about the signs and symptoms of such an allergic reaction so the patient will return to us sooner for treatment.
Written informed consent was obtained from the patient for publication of this Case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
No funding was necessary for this article.
- Wilson FM: Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc. 1983, 81: 854-965.PubMedPubMed CentralGoogle Scholar
- Wilson , Fred M: Allergy to Topical Medications. International Ophthalmology Clinics. Recent Trends in Ocular Allergy. 2003, 43 (1): 73-81. WinterGoogle Scholar
- Wilson FM: Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol. 1979, 24: 57-88. 10.1016/0039-6257(79)90125-5.View ArticlePubMedGoogle Scholar
- Stern GA, Knapp A: Iatrogenic peripheral corneal disease. Int Ophthalmol Clin. 1986, 26: 77-89. 10.1097/00004397-198602640-00008.View ArticlePubMedGoogle Scholar
- Wise DJ, Carter GR: Immunology. A comprehensive review. 2002, Ames, Iowa: Iowa State University PressGoogle Scholar
- Baldinger J, Weiter JJ: Diffuse cutaneous hypersensitivity reaction after dexamethasone/polymyxin B/neomycin combination eye drops. Source Annals of Ophthalmology. 1986, 18 (3): 95-6.Google Scholar
- de Pádua CA, Uter W, Schnuch A: Contact allergy to topical drugs: prevalence in a clinical setting and estimation of frequency at the population level. Pharmacoepidemiol Drug Saf. 2007, 16 (4): 377-84. 10.1002/pds.1268.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.